Literature DB >> 21514828

King-Denborough syndrome with and without mutations in the skeletal muscle ryanodine receptor (RYR1) gene.

James J Dowling1, Suzanne Lillis, Kimberley Amburgey, Haiyan Zhou, Safa Al-Sarraj, Stefan J A Buk, Elizabeth Wraige, Gabby Chow, Stephen Abbs, Steven Leber, Katherine Lachlan, Diana Baralle, Alexandra Taylor, Caroline Sewry, Francesco Muntoni, Heinz Jungbluth.   

Abstract

King-Denborough syndrome (KDS), first described in 1973, is a rare condition characterised by the triad of dysmorphic features, myopathy, and malignant hyperthermia susceptibility (MHS). Autosomal dominant inheritance with variable expressivity has been reported in several cases. Mutations in the skeletal muscle ryanodine receptor (RYR1) gene have been implicated in a wide range of myopathies such as central core disease (CCD), the malignant hyperthermia (MH) susceptibility trait and one isolated patient with KDS. Here we report clinical, pathologic and genetic features of four unrelated patients with KDS. Patients had a relatively uniform clinical presentation but muscle biopsy findings were highly variable. Heterozygous missense mutations in RYR1 were uncovered in three out of four families, of which one mutation was novel and two have previously been reported in MH. Further RyR1 protein expression studies performed in two families showed marked reduction of the RyR1 protein, indicating the presence of allelic RYR1 mutations not detectable on routine sequencing and potentially explaining marked intrafamilial variability. Our findings support the hypothesis that RYR1 mutations are associated with King-Denborough syndrome but that further genetic heterogeneity is likely.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21514828     DOI: 10.1016/j.nmd.2011.03.006

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  26 in total

1.  Clinical utility gene card for: Central core disease.

Authors:  Suzanne Lillis; Stephen Abbs; Clemens R Mueller; Francesco Muntoni; Heinz Jungbluth
Journal:  Eur J Hum Genet       Date:  2011-10-12       Impact factor: 4.246

2.  Understanding Symptoms in RYR1-Related Myopathies: A Mixed-Methods Analysis Based on Participants' Experience.

Authors:  Carlos Capella-Peris; Mary M Cosgrove; Irene C Chrismer; M Sonia Razaqyar; Jeffrey S Elliott; Anna Kuo; Magalie Emile-Backer; Katherine G Meilleur
Journal:  Patient       Date:  2020-08       Impact factor: 3.883

Review 3.  Swimming into prominence: the zebrafish as a valuable tool for studying human myopathies and muscular dystrophies.

Authors:  Elizabeth M Gibbs; Eric J Horstick; James J Dowling
Journal:  FEBS J       Date:  2013-07-25       Impact factor: 5.542

4.  Mouse model of severe recessive RYR1-related myopathy.

Authors:  Stephanie Brennan; Maricela Garcia-Castañeda; Antonio Michelucci; Nesrin Sabha; Sundeep Malik; Linda Groom; Lan Wei LaPierre; James J Dowling; Robert T Dirksen
Journal:  Hum Mol Genet       Date:  2019-09-15       Impact factor: 6.150

5.  Consensus statement on standard of care for congenital myopathies.

Authors:  Ching H Wang; James J Dowling; Kathryn North; Mary K Schroth; Thomas Sejersen; Frederic Shapiro; Jonathan Bellini; Hali Weiss; Marc Guillet; Kimberly Amburgey; Susan Apkon; Enrico Bertini; Carsten Bonnemann; Nigel Clarke; Anne M Connolly; Brigitte Estournet-Mathiaud; Dominic Fitzgerald; Julaine M Florence; Richard Gee; Juliana Gurgel-Giannetti; Allan M Glanzman; Brittany Hofmeister; Heinz Jungbluth; Anastassios C Koumbourlis; Nigel G Laing; Marion Main; Leslie A Morrison; Craig Munns; Kristy Rose; Pamela M Schuler; Caroline Sewry; Kari Storhaug; Mariz Vainzof; Nanci Yuan
Journal:  J Child Neurol       Date:  2012-03       Impact factor: 1.987

Review 6.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes.

Authors:  Stephen G Gonsalves; Robert T Dirksen; Katrin Sangkuhl; Rebecca Pulk; Maria Alvarellos; Teresa Vo; Keiko Hikino; Dan Roden; Teri E Klein; S Mark Poler; Sephalie Patel; Kelly E Caudle; Ronald Gordon; Barbara Brandom; Leslie G Biesecker
Journal:  Clin Pharmacol Ther       Date:  2019-01-24       Impact factor: 6.875

7.  Congenital myopathies: Natural history of a large pediatric cohort.

Authors:  Irene Colombo; Mariacristina Scoto; Adnan Y Manzur; Stephanie A Robb; Lorenzo Maggi; Vasantha Gowda; Thomas Cullup; Michael Yau; Rahul Phadke; Caroline Sewry; Heinz Jungbluth; Francesco Muntoni
Journal:  Neurology       Date:  2014-11-26       Impact factor: 9.910

8.  A novel late-onset axial myopathy associated with mutations in the skeletal muscle ryanodine receptor (RYR1) gene.

Authors:  Sissel Løseth; Nicol C Voermans; Torberg Torbergsen; Sue Lillis; Christoffer Jonsrud; Sigurd Lindal; Erik-Jan Kamsteeg; Martin Lammens; Marcus Broman; Gabriele Dekomien; Paul Maddison; Francesco Muntoni; Caroline Sewry; Aleksandar Radunovic; Marianne de Visser; Volker Straub; Baziel van Engelen; Heinz Jungbluth
Journal:  J Neurol       Date:  2013-01-18       Impact factor: 4.849

Review 9.  Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept.

Authors:  Sheila Riazi; Natalia Kraeva; Philip M Hopkins
Journal:  Anesthesiology       Date:  2018-01       Impact factor: 7.892

Review 10.  Triadopathies: an emerging class of skeletal muscle diseases.

Authors:  James J Dowling; Michael W Lawlor; Robert T Dirksen
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.